Related Experiment Video

Updated: Jun 27, 2026

Osteoclast Derivation from Mouse Bone Marrow
06:17

Osteoclast Derivation from Mouse Bone Marrow

Published on: November 6, 2014

Beta2-adrenoreceptor ligands regulate osteoclast differentiation in vitro by direct and indirect mechanisms

Sarah J Aitken1, Euphemie Landao-Bassonga, Stuart H Ralston

  • 1Rheumatic Diseases Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK.

Archives of Biochemistry and Biophysics
|December 9, 2008
PubMed

Insights

Beta-adrenoceptor agonists, like those targeting beta2-adrenoceptors, stimulate bone resorption by increasing osteoclast formation. However, these compounds do not directly impact osteoblast growth or function, clarifying their role in bone regulation.

Area of Science:

  • Bone biology
  • Pharmacology
  • Endocrinology

Background:

  • Beta-adrenoceptors modulate bone mineral density and fracture risk.
  • Beta-adrenoceptor ligands are known to stimulate bone resorption via RANK-L.
  • Mechanisms of beta-adrenoceptor regulation of bone formation remain unclear.

Purpose of the Study:

  • To investigate the role of beta-adrenoceptors in bone cell function.
  • To elucidate the effects of beta2-adrenoceptor agonists on osteoblasts and osteoclasts.
  • To understand the impact of the sympathetic nervous system on bone mass regulation.

Main Methods:

  • Analysis of beta-adrenoceptor expression in bone cells.
  • Co-culture of bone marrow (BM) osteoblasts and osteoclasts.
  • Treatment with noradrenaline and selective beta2-adrenoceptor agonists (isoprenaline, salmeterol).
  • Assessment of osteoclast formation, bone resorption, and osteoblast function.

Main Results:

  • Beta2-adrenoceptor is predominantly expressed by bone cells; beta1 and beta3 receptors are detected at lower levels.
  • Noradrenaline and beta2-agonists stimulated osteoclast formation and bone resorption.
  • These ligands increased osteoblast expression of RANK-L.
  • No significant effects observed on osteoblast growth, differentiation, or function.

Conclusions:

  • Pharmacological agonists of beta2-adrenoceptors directly and indirectly stimulate osteoclast formation and bone resorption.
  • These agonists do not exert direct effects on osteoblast growth, differentiation, or function.
  • Findings confirm the sympathetic nervous system's role in regulating bone mass through beta2-adrenoceptor pathways.

More Related Videos

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro07:03

A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro

Published on: June 16, 2022

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...